Anticoagulants

Summary

The world anticoagulants market is driven by patent expiries, development of novel therapeutics, and rapidly aging population. With just two therapy classes - vitamin K antagonist and heparin injectables, dominating the market, there exist enormous opportunities and interest in developing advanced, patient friendly anticoagulants. Favorable demographic patterns, like the rapidly aging world population is expected to drive demand patterns, given the tendency of aging individuals to develop various venous and arterial complications.

The unmet medical needs of available anticoagulants offer ample scope for development in the world anticoagulants market. Continuous research and development is expected to result in novel therapies with superior therapeutic efficiency, and minimum side effects. These advanced therapeutics offer promising market prospects. Identification of new indications for existing, and emerging therapies is expected to help open up brighter prospects for further growth. Factor Xa inhibitors (oral and injectable) and direct thrombin inhibitors (oral and injectable) are among the new class of thrombin antagonists that are being evaluated for both existing as well as newer indications.

These and other market data and trends are presented in "Anticoagulants: A Global Market Review" by BizAcumen LLC. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Contents

• 1.Methodology
  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Quantitative Techniques & Reporting Level
• 2.Global Market Overview and Outlook
• 3.Market Scenario
  • A Snapshot of Available Therapies
  • An Insight into Currently Available Antithrombotic Drugs
  • Weaknesses of Available Therapies
  • Forces Driving The Market
  • Oral Anticoagulants Market
  • Injectable Anticoagulants Market
  • Heparin Market
  • Lmwh Market
• 4.Market Dynamics
  • Drug Advancements Drive Anticoagulant Market
  • Niche Markets - The New Target for Drug Makers
  • An Opportunity to Grow Further
  • Geriatric Patients - at High Risk of Blood Clots
  • Improved Anticoagulant Agents for Children Group
  • Growing Demand for Self-Testing
  • Lmwhs Eases Outpatient Management
  • Concern over Underutilization of Warfarin
  • Anticoagulants to Lose Ua/Ami Markets to Antiplatelets
  • Influx of New Drugs Invigorates The Market
  • Novel Heparins Enhances Market Potential
  • Anticoagulant Therapy during Pregnancy Improves Outcomes
  • New Therapies: Need of The Hour
  • Anticoagulant Therapy in Ipf: Reduces Mortality Risk
  • Failure of Exanta
• 5.Product Facts
  • Anticoagulants
  • Indications for Anticoagulant Use
  • List of Approved Anticoagulants for Pulmonary Embolism
  • List of Approved Anticoagulants for Orthopedic Surgery
  • List of Approved Anticoagulants for General Surgery
  • List of Approved Anticoagulants for Atrial Fibrillation
  • List of Approved Anticoagulants for Unstable Angina
  • List of Approved Anticoagulants for Non-St Segment Elevation Myocardial Infraction
  • List of Approved Anticoagulants for Angioplasty Procedures
  • List of Approved Anticoagulants for Hit Type Ii
• 6.Drug Development Pipeline
  • Select Anticoagulants under Pipeline
  • Idraparinux - Sanofi-Aventis
• 0673 - Sanofi-Aventis
  • Bibr1048ms - Boehringer Ingelheim
• 7.Corporate Developments
  • Paion Acquires Cenes Pharmaceuticals
  • Paion Announces Acquisition of Global Rights to Trigen's Flovagatran
  • Biological E Collaborates with Choncept and Heparinex
  • Bayer's Market Expansion
  • B. Braun Recalls Heparin Sodium Based Injection Solutions
  • Baxter Recalls Heparin Sodium Vials
  • Boehringer Receives Eu Approval for Pradaxa
  • Sanofi-Aventis Receives Approval for Clexane in Japan
  • Paragondx Receives US Fda Approval for Its Rapid Genotyping Assay
  • Lannett Obtains US Fda Approval for Dipyridamole Tablets
  • Celgene Acquires Pharmion
  • Bms Collaborates with Pfizer
  • Medicines Company Reacquires European Rights for Angiox
  • Hemosense and Labcorp Sign Agreement for Supply of Inratio System
  • Sanofi-Aventis Acquires Rights for Panaldine from Daiichi
  • Alchemia Inks Marketing Alliance with Dr Reddy's for Heparin
  • Inverness Announces Acquisition of Hemosense
  • Ev3, Foxhollow Complete Merger
  • Osmetech Signs Licensing Agreement with Marshfield Clinic
  • Mitsubishi and Tanabe Agree to Merge
  • Artisan and A-Bio Form Alliance
  • Kimball Introduces New Pharmacogenetic Test
  • Roche Launches An Improved Point-of- Care Anticoagulation Monitoring System
  • Danish Agency Grants Approval for Anticoagulant Clinical Trials
  • Emea Approves Arixtra of Glaxosmithkline
  • Fda Approves Andas of Pliva
  • Fda Approves Arixtra Injection of Gsk
  • Japanese Ministry Approves Arixtra of Gsk
  • Eisai Obtains Fda Approval for Fragmin
  • Sanofi-Aventis' Lovenox Obtains Fda Approval for Acute Cardiac Care
• 8.Major Players
  • Astrazeneca Plc (UK)
  • Bristol-Myers Squibb Company (USA)
  • Celgene Corporation (USA)
  • Glaxosmithkline Plc (UK)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Pfizer Inc. (USA)
  • Sanofi-Aventis (France)
• 9.Market Analytics
• 10.The United States
  • Atrial Fibrillation - A Key Risk Factor
  • Regulatory Route to The US Market
  • Phase I Clinical Trials
  • Phase Ii Clinical Trials
  • Phase Iii Clinical Trials
  • Price Controls
  • US Anticoagulants Market
  • US Heparin Market
  • Hinging on Market Opportunities
  • Generics - Threatening Branded Anticoagulants
  • List of Patent Protected Anticoagulants in The US
  • Ignorance - A Major Hindrance
  • Future Challenges and Growth Drivers
  • US Emerging Anticoagulant Market
  • US Emerging Anticoagulants Market: Products in The Pipeline
• 11.Japan
  • Anticoagulants Market in Japan
  • Rising Incidence of Pulmonary Thromboembolism
• 12.Europe
  • A.France
  • B.Germany
  • C.Italy
  • D.The United Kingdom
  • E.Spain
  • F.Rest of Europe
• 13.Rest of World
  • Table 1: Global Anticoagulants Market by Region for The Period 2007-2015 (Sales in US$ Million)
  • Table 2: Percentage Breakdown of Global Anticoagulants Market by Region for The Years 2008 &
  • Table 3: Global Oral Anticoagulants Market by Region for The Period 2007-2015 (Sales in US$ Million)
  • Table 4: Percentage Breakdown of Global Oral Anticoagulants Market by Region for The Years 2008 &
  • Table 5: Global Injectable Anticoagulants Market by Region for The Period 2007-2015 (Sales in US$ Million)
  • Table 6: Percentage Breakdown of Global Injectable Anticoagulants Market by Region for The Years 2008 &
  • Table 7: Global Injectable Anticoagulants Market by Segment for The Period 2007-2015 (Sales in US$ Million)
  • Table 8: Percentage Breakdown of Global Injectable Anticoagulants Market by Segment for The Years 2008 &
  • Table 9: Global Unfractionated Heparin Market by Region for The Period 2007-2015 (Sales in US$ Million)
  • Table 10: Percentage Breakdown of Global Unfractionated Heparin Market by Region for The Years 2008 &
  • Table 11: Global Low Molecular Weight Heparin Market by Region for The Period 2007-2015 (Sales in US$ Million)
  • Table 12: Percentage Breakdown of Global Low Molecular Weight Heparin Market by Region for The Years 2008 &
  • Table 13: Anticoagulants Market by Segment in The US: 2007-2015 (Sales in US$ Million)
  • Table 14: Percentage Breakdown of Anticoagulants Market by Segment in The US for The Years 2008 &
  • Table 15: Anticoagulants Market by Segment in Japan: 2007-2015 (Sales in US$ Million)
  • Table 16: Percentage Breakdown of Anticoagulants Market by Segment in Japan for The Years 2008 &
  • Table 17: Anticoagulants Market by Region in Europe: 2007-2015 (Sales in US$ Million)
  • Table 18: Percentage Breakdown of Anticoagulants Market by Region in Europe for The Years 2008 &
  • Table 19: Anticoagulants Market by Segment in Europe: 2007-2015 (Sales in US$ Million)
  • Table 20: Percentage Breakdown of Anticoagulants Market by Segment in Europe for The Years 2008 &
  • Table 21: Anticoagulants Market by Segment in France: 2007-2015 (Sales in US$ Million)
  • Table 22: Percentage Breakdown of Anticoagulants Market by Segment in France for The Years 2008 &
  • Table 23: Anticoagulants Market by Segment in Germany: 2007-2015 (Sales in US$ Million)
  • Table 24: Percentage Breakdown of Anticoagulants Market by Segment in Germany for The Years 2008 &
  • Table 25: Anticoagulants Market by Segment in Italy: 2007-2015 (Sales in US$ Million)
  • Table 26: Percentage Breakdown of Anticoagulants Market by Segment in Italy for The Years 2008 &
  • Table 27: Anticoagulants Market by Segment in The UK: 2007-2015 (Sales in US$ Million)
  • Table 28: Percentage Breakdown of Anticoagulants Market by Segment in The UK for The Years 2008 &
  • Table 29: Anticoagulants Market by Segment in Spain: 2007-2015 (Sales in US$ Million)
  • Table 30: Percentage Breakdown of Anticoagulants Market by Segment in Spain for The Years 2008 &
  • Table 31: Anticoagulants Market by Segment in The Rest of Europe: 2007-2015 (Sales in US$ Million)
  • Table 32: Percentage Breakdown of Anticoagulants Market by Segment in The Rest of Europe for The Years 2008 &
  • Table 33: Anticoagulants Market by Segment in Rest of World: 2007-2015 (Sales in US$ Million)
  • Table 34: Percentage Breakdown of Anticoagulants Market by Segment in Rest of World for The Years 2008 &
• Companies Profiled